Loading...
The prognosis for patients with advanced immunoglobulin light chain amyloidosis (AL) has improved with the use of several drugs that are approved for the treatment of multiple myeloma. Recently, daratumumab, a human anti–CD 38 monoclonal antibody, has been introduced for the management of relapsed or refractory multiple myeloma.
To determine whether daratumumab is safe and effective in advanced multisystem AL amyloidosis, investigators treated two patients that were in relapse after stem-cell transplant and combination chemotherapy with carfilzomib, cyclophosphamide, and dexamethasone. Daratumumab was given in eight weekly intravenous infusions in doses currently approved for myeloma therapy.
Clinical improvement occurred in both patients dur…